Last reviewed · How we verify
LCZ 696
LCZ696 is a dual angiotensin receptor-neprilysin inhibitor (ARNI) that blocks angiotensin II signaling while inhibiting neprilysin to increase natriuretic peptides.
LCZ696 is a dual angiotensin receptor-neprilysin inhibitor (ARNI) that blocks angiotensin II signaling while inhibiting neprilysin to increase natriuretic peptides. Used for Heart failure with reduced ejection fraction, Hypertension.
At a glance
| Generic name | LCZ 696 |
|---|---|
| Also known as | Entresto®), ARNI, Entresto, sacubitril/valsartan |
| Sponsor | National Medical Research Center for Cardiology, Ministry of Health of Russian Federation |
| Drug class | Angiotensin receptor-neprilysin inhibitor (ARNI) |
| Target | Angiotensin II type 1 receptor (AT1R); Neprilysin |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
LCZ696 combines valsartan (an ARB) with sacubitril (a neprilysin inhibitor) in a single molecule. By blocking AT1 receptors, it reduces vasoconstriction and aldosterone secretion; simultaneously, neprilysin inhibition prevents degradation of natriuretic peptides, enhancing their beneficial vasodilatory and diuretic effects. This dual mechanism provides superior hemodynamic and neurohormonal benefits compared to ACE inhibitors or ARBs alone.
Approved indications
- Heart failure with reduced ejection fraction
- Hypertension
Common side effects
- Hypotension
- Hyperkalemia
- Cough
- Dizziness
- Renal impairment
Key clinical trials
- Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction
- Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy (NA)
- Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets (PHASE1)
- Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3 (PHASE4)
- Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan (PHASE1, PHASE2)
- A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan
- A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction (PHASE1)
- A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: